Trulieve Cannabis: Strong Financial Performance and Strategic Management Justify Buy Rating

Analyst Neal Gilmer of Haywood maintained a Buy rating on Trulieve Cannabis (TCNNF – Research Report), retaining the price target of C$15.00.

Neal Gilmer has given his Buy rating due to a combination of factors, including Trulieve Cannabis’s strong financial performance in the first quarter of 2025. The company reported impressive gross margins that exceeded expectations, leading to an EBITDA margin that also surpassed forecasts. This strong financial showing was bolstered by a revenue figure that, while slightly down sequentially, still outperformed estimates.
Trulieve’s ability to generate significant operating and free cash flow, despite substantial campaign contributions, further supports the Buy rating. The company’s solid cash position, along with its strategic financial management, indicates a robust foundation for future growth. These factors, combined with a favorable revision of future estimates, underpin Neal Gilmer’s positive outlook on Trulieve’s stock.

Gilmer covers the Healthcare sector, focusing on stocks such as OrganiGram Holdings, Green Thumb Industries, and Trulieve Cannabis. According to TipRanks, Gilmer has an average return of -11.1% and a 35.54% success rate on recommended stocks.